Researchers compare breast cancer drugs
Oct 24, 2011
A new study published in The Lancet Oncology studied the effects of the breast cancer drug letrozolem, which is marketed as Femara, and tamoxifen. The researchers found that the Femara may be more effective against breast cancer recurrence and improving survival for those with hormone-sensitive breast cancers.
The researchers studied approximately 8,000 women and compared them in three groups - one who took the Femara, one the tamoxifen and one with both. It was determined that Femara outperformed tamoxifen in both survival and recurrence, according to the news source.
"Femara alone is the best way to go," Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York City, told the media outlet. "The hope was that the combination would improve survival, but this was not the case."
According to the Susan G. Komen Foundation, it is recommended that once a woman turns 40 she schedules annual mammograms. If a woman has an extensive family history of breast cancer, she may want to start planning these appointments earlier to ensure that she does not have the disease and if she does that it was caught during its beginning stages.